Dual-hormone artificial pancreas for glucose control in type 1 diabetes: A meta-analysis.

ABSTRACT:

Aim

To evaluate the efficacy and safety of a dual-hormone artificial pancreas (DH) in type 1 diabetes.

Material and methods

PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched for studies published up to February 16, 2022. We included randomized controlled trials that compared DH with single-hormone artificial pancreas (SH), continuous subcutaneous insulin infusion (CSII) or sensor-augmented pumps (SAP), and predictive low glucose suspend systems (PLGS) in type 1 diabetes. The primary outcome was percent time in target (3.9-10 mmol/L [70-180 mg/dL]). Data were summarized as mean differences (MDs) or risk differences (RDs).

Results

A total of 17 randomized crossover trials (438 participants) were included. There were nine trials of DH versus SH, 1

SUBMITTER: Zeng B 

PROVIDER: S-EPMC9542047 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature